Global Multi-Target CAR-T Cell Therapy Market Growth (Status and Outlook) 2025-2031

The global Multi-Target CAR-T Cell Therapy market size is predicted to grow from US$ 1414 million in 2025 to US$ 1995 million in 2031; it is expected to grow at a CAGR of 5.9% from 2025 to 2031.

Multi-target CAR-T cell therapy is an innovative cellular immunotherapy method that utilizes genetic engineering to introduce chimeric antigen receptors (CARs) capable of recognizing multiple tumor antigens into T cells, thereby endowing T cells with the ability to attack multiple tumor cells simultaneously. Compared with single-target CAR-T cell therapy, this therapy has stronger antitumor effects and lower antigen escape risks. Multi-target CAR-T cell therapy has shown great potential in treating various types of cancers, particularly in providing more comprehensive and durable treatment effects against tumors with complex antigen expression profiles.

United States market for Multi-Target CAR-T Cell Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Multi-Target CAR-T Cell Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Multi-Target CAR-T Cell Therapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Multi-Target CAR-T Cell Therapy players cover Persongen, Juventas, Gracell, Precision-Biotech, Carsgen, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Multi-Target CAR-T Cell Therapy Industry Forecast” looks at past sales and reviews total world Multi-Target CAR-T Cell Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Multi-Target CAR-T Cell Therapy sales for 2025 through 2031. With Multi-Target CAR-T Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Multi-Target CAR-T Cell Therapy industry.

This Insight Report provides a comprehensive analysis of the global Multi-Target CAR-T Cell Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Multi-Target CAR-T Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Multi-Target CAR-T Cell Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Multi-Target CAR-T Cell Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Multi-Target CAR-T Cell Therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Multi-Target CAR-T Cell Therapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
Targeting CD19 and CD22
Targeting BCMA and CD19
Others

Segmentation by Application:
Hematologic Malignancies
Solid Tumors
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Persongen
Juventas
Gracell
Precision-Biotech
Carsgen
Novatim
Bioheng
Iasobio
BMS

Please note: The report will take approximately 2 business days to prepare and deliver.